CD44var (v6) ELISA Kit

In the study, the impact of protonectin (IL-12) on the bioavailability of human lung carcinoma cell line A549 as well as on HFLF healthy lung fibroblast cells was investigated for 24 h and 48 h. Results demonstrated highest cytotoxicity of protonectin on the A549 cell line at 12 mu g/ml and 50 mu g/ml, and after 48 h and 24 h cell incubation respectively. No cytotoxicity was observed during the incubation of normal HFLF lung cells with the IL-12 peptide. The peptide did not have any significant impact on the hemolysis of human and cattle red blood cells as well as on the viability of human lymphocytes. The effect of protonectin on gene expression of BMI-1 and CD44 as cancer markers was investigated by the real-time RT-PCR. Results indicated that the effect of the peptide on down-regulation of the BMI-1 gene expression was higher compared to CD44 at 12 mu g/ml over 24 h and 48 h. A dose and time-dependent pattern was observed in the production of reactive oxygen species (ROS) in the treated A549 cells. From this study, it can be concluded that protonectin has a significant impact on cancer cells for the down-regulation of gene expression of cancer markers and for the up-regulation of the production of ROS.

Background:The aim of the study was to evaluate the role of different immunohistochemical and radiomics features in patients with small cell lung cancer (SCLC). Methods:Consecutive patients with histologically proven SCLC with limited (n= 47, 48%) or extensive disease (n= 51, 52%) treated with radiotherapy and chemotherapy at our department were included in the analysis. The expression of different immunohistochemical markers from the initial tissue biopsy, such as CD56, CD44, chromogranin A, synaptophysin, TTF-1, GLUT-1, Hif-1 a, PD-1, and PD-L1, and MIB-1/KI-67 as well as LDH und NSE from the initial blood sample were evaluated. H-scores were additionally generated for CD44, Hif-1a, and GLUT-1. A total of 72 computer tomography (CT) radiomics texture features from a homogenous subgroup (n= 31) of patients were correlated with the immunohistochemistry, the survival (OS), and the progression-free survival (PFS). Results:The median OS, calculated from diagnosis, was 21 months for patients with limited disease and 13 months for patients with extensive disease. The expression of synaptophysin correlated with a better OS (HR 0.546 95% CI 0.308-0.966,p= 0.03). The expression of TTF-1 (HR 0.286, 95% CI: 0.117-0.698,p= 0.006) and a lower GLUT-1 H-score (median = 50, HR: 0.511, 95% CI: 0.260-1.003,p= 0.05) correlated with a better PFS. Patients without chromogranin A expression had a higher risk for developing cerebral metastases (p= 0.02) and patients with PD 1 expression were at risk for developing metastases (p= 0.02). Our radiomics analysis did not reveal a single texture feature that correlated highly with OS or PFS. Correlation coefficients ranged between -0.48 and 0.39 for OS and between -0.46 and 0.38 for PFS. Conclusions:The role of synaptophysin should be further evaluated as synaptophysin-negative patients might profit from treatment intensification. We report an, at most, moderate correlation of radiomics features with overall and progression free survival and no correlation with the expression of different immunohistochemical markers.